This company seems to have been delisted
Reason: Acquired by AstraZeneca
Last recorded trade on: April 26, 2024
Source: https://www.astrazeneca.com/media-centre/press-releases/2024/acquisition-of-gracell-completed.htmlherapy%20ambition.
Reason: Acquired by AstraZeneca
Last recorded trade on: April 26, 2024
Source: https://www.astrazeneca.com/media-centre/press-releases/2024/acquisition-of-gracell-completed.htmlherapy%20ambition.
Gracell Biotechnologies
GRCL
$13.67
Share price
0.00%
Change (1 day)
173.29%
Change (1 year)
Categories
Revenue for Gracell Biotechnologies (GRCL)
Revenue in 2023 (TTM): N/A
In 2022 the company made a revenue of N/A a decrease over the revenue in the year 2021 that were of S$0.07 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Gracell Biotechnologies from 2020 to 2023
Annual revenue
| Year | Revenue | Change |
|---|---|---|
2023 (TTM)  | N/A | |
| 2022 | N/A | -100% |
| 2021 | S$0.07 M | |
| 2020 | N/A |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 | N/A | N/A | 🇺🇸 USA |